Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Potential Survival Benefit of Upfront Surgery for Lung Tumors Unconfirmed but Highly Suspicious for Stage I Lung Cancer

  • Murat Kara (Department of Thoracic Surgery, Istanbul University Medical Faculty) ;
  • Eren Erdogdu (Department of Thoracic Surgery, Istanbul University Medical Faculty) ;
  • Salih Duman (Department of Thoracic Surgery, Istanbul University Medical Faculty) ;
  • Gulnar Fatalizade (Department of Thoracic Surgery, Istanbul University Medical Faculty) ;
  • Berker Ozkan (Department of Thoracic Surgery, Istanbul University Medical Faculty) ;
  • Alper Toker (Department of Cardiovascular and Thoracic Surgery, West Virginia University Heart and Vascular Institute)
  • Received : 2023.11.29
  • Accepted : 2024.02.26
  • Published : 2024.09.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Patients with early-stage lung tumors that are highly suspicious for malignancy typically undergo a preoperative diagnostic workup, primarily through bronchoscopy or transthoracic biopsy. Those without a preoperative diagnosis may alternatively be treated with upfront surgery, contingent upon the potential for intraoperative diagnosis. Previous studies have yielded conflicting results regarding the impact of upfront surgery on the survival of these patients. Our study aimed to elucidate the effect of upfront surgery on the survival outcomes of patients undergoing surgery for early-stage lung cancer without a preoperative diagnosis. Methods: We analyzed the survival rate of 158 consecutive patients who underwent pulmonary resection for stage I lung cancer, either with or without a preoperative diagnosis. Results: A total of 86 patients (54%) underwent upfront surgery. This approach positively impacted both disease-free survival (p=0.031) and overall survival (p=0.017). However, no significant differences were observed across subgroups based on sex, smoking status, forced expiratory volume in 1 second, histologic tumor size, or histologic subtype. Univariate analysis identified upfront surgery (p=0.020), age (p=0.002), maximum standardized uptake value (SUVmax) exceeding 7 (p=0.001), and histological tumor size greater than 20 mm (p=0.009) as independent predictors. However, multivariate analysis indicated that only SUVmax greater than 7 (p=0.011) was a significant predictor of unfavorable survival. Conclusion: Upfront surgery does not appear to confer a survival advantage in patients with stage I lung cancer undergoing surgical intervention.

Keywords

References

  1. Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:497-530. https://doi.org/10.6004/jnccn.2022.0025
  2. Nakajima J, Sato H, Takamoto S. Does preoperative transbronchial biopsy worsen the postsurgical prognosis of lung cancer?: a propensity score-adjusted analysis. Chest 2005;128:3512-8. https://doi.org/10.1378/chest.128.5.3512
  3. Abe J, Okazaki T, Kikuchi N, Takahashi S, Sakurada A, Okada Y. Preoperative bronchoscopic cancer confirmation does not increase risk of recurrence in stage1A non-small cell lung cancer. Gen Thorac Cardiovasc Surg 2018;66:284-90. https://doi.org/10.1007/s11748-018-0909-y
  4. Yasukawa M, Kawaguchi T, Kimura M, Tojo T, Taniguchi S. Implications of preoperative transbronchial lung biopsy for non-small cell lung cancer less than 3-cm. In Vivo 2021;35:1027-31. https://doi.org/10.21873/invivo.12346
  5. Taniguchi Y, Fukumoto K, Matsui H, Saito T, Murakawa T. Preoperative biopsy does not affect postoperative outcomes of resectable non-small cell lung cancer. Gen Thorac Cardiovasc Surg 2019;67:615-23. https://doi.org/10.1007/s11748-019-01062-1
  6. Sihoe AD, Hiranandani R, Wong H, Yeung ES. Operating on a suspicious lung mass without a preoperative tissue diagnosis: pros and cons. Eur J Cardiothorac Surg 2013;44:231-7. https://doi.org/10.1093/ejcts/ezs671
  7. Kara M, Alver G, Sak SD, Kavukcu S. Implantation metastasis caused by fine needle aspiration biopsy following curative resection of stage IB non-small cell lung cancer. Eur J Cardiothorac Surg 2001;20:868-70. https://doi.org/10.1016/s1010-7940(01)00866-1
  8. Sawabata N, Maeda H, Ohta M, Hayakawa M. Operable non-small cell lung cancer diagnosed by transpleural techniques : do they affect relapse and prognosis? Chest 2001;120:1595-8. https://doi.org/10.1378/chest.120.5.1595
  9. Mayne NR, Elser HC, Darling AJ, et al. Estimating the impact of extended delay to surgery for stage I non-small-cell lung cancer on survival. Ann Surg 2021;273:850-7. https://doi.org/10.1097/SLA.0000000000004811.
  10. Klarenbeek SE, Aarts MJ, van den Heuvel MM, Prokop M, Tummers M, Schuurbiers OC. Impact of time-to-treatment on survival for advanced non-small cell lung cancer patients in the Netherlands: a nationwide observational cohort study. Thorax 2023;78:467-75. https://doi.org/10.1136/thoraxjnl-2021-218059
  11. Tsai CH, Kung PT, Kuo WY, Tsai WC. Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: a national cohort study in Taiwan. BMJ Open 2020;10:e034351. https://doi.org/10.1136/bmjopen-2019-034351
  12. Xu L, Zhang G, Song S, Zheng Z. Prognostic factors, treatment, and outcomes in combined small cell lung cancer: a SEER survey from 2004 to 2015. Transl Cancer Res 2020;9:5292-303. https://doi.org/10.21037/tcr-20-968
  13. Woo HS, Song JW, Park S, Park IK, Kang CH, Kim YT. Clinical outcomes after upfront surgery in clinical stage I-IIA small cell lung cancer. J Chest Surg 2022;55:470-7. https://doi.org/10.5090/jcs.22.085